[1]李 璟,李雯婷,熊耀翼,等.2型糖尿病合并桥本甲状腺炎患者血清巨噬细胞炎症蛋白-1α、程序性死亡因子-1检测及预测价值[J].陕西医学杂志,2025,54(3):389-393.[doi:DOI:10.3969/j.issn.1000-7377.2025.03.020]
　LI Jing,LI Wenting,XIONG Yaoyi,et al.Changes and predictive value of serum MIP-1α and PD-1 levels in patients with type 2 diabetes mellitus complicated with Hashimoto's thyroiditis[J].,2025,54(3):389-393.[doi:DOI:10.3969/j.issn.1000-7377.2025.03.020]
点击复制

2型糖尿病合并桥本甲状腺炎患者血清巨噬细胞炎症蛋白-1α、程序性死亡因子-1检测及预测价值
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
54
期数:
2025年3期
页码:
389-393
栏目:
临床检验
出版日期:
2025-03-05

文章信息/Info

Title:
Changes and predictive value of serum MIP-1α and PD-1 levels in patients with type 2 diabetes mellitus complicated with Hashimoto's thyroiditis
作者:
李 璟1; 李雯婷2; 熊耀翼3; 沈轩宇4
(1.成都中医药大学第三附属医院检验科,四川 成都 610031; 2.成都中医药大学第三附属医院内分泌科,四川 成都 610031; 3.四川省第四人民医院检验科,四川 成都 610011; 4.四川省中西医结合医院检验科,四川 成都 610041)
Author(s):
LI Jing1; LI Wenting2; XIONG Yaoyi3; SHEN Xuanyu4
(1.Department of Clinical Laboratory,the Third Affiliated Hospital of Chengdu University of Traditional Chinese Medicine,Chengdu 610031,China; 2.Department of Endocrinology,the Third Affiliated Hospital of Chengdu University of Traditional Chinese Medicine,Chengdu 610031,China; 3.Department of Clinical Laboratory,the Fourth People's Hospital of Sichuan Province,Chengdu 610011,China; 4.Department of Clinical Laboratory,Sichuan Hospital of Integrated Traditional Chinese and Western Medicine,Chengdu 610041,China)
关键词:
2型糖尿病;  桥本甲状腺炎;  巨噬细胞炎症蛋白-1α;  程序性死亡因子-1;  危险因素;  预测价值
Keywords:
Type 2 diabetes mellitus;  Hashimoto's thyroiditis;  Macrophage inflammatory protein-1α;  Programmed cell death-1;  Risk factors;  Predictive value
分类号:
R 578.1
DOI:
DOI:10.3969/j.issn.1000-7377.2025.03.020
文献标志码:
A
摘要:
目的:检测2型糖尿病(T2DM)合并桥本甲状腺炎(HT)患者血清巨噬细胞炎症蛋白-1α(MIP-1α)和程序性死亡因子-1(PD-1)水平,并分析它们对T2DM合并HT的预测价值。方法:选取T2DM合并HT患者46例为研究组,选取同期单纯T2DM患者53例为糖尿病组,选取体检健康者42例为对照组。比较血清MIP-1α、PD-1水平及甲状腺功能相关指标; Pearson法分析血清MIP-1α、PD-1与甲状腺功能相关指标的相关性; Logistic回归分析T2DM合并HT的影响因素; 受试者工作特征(ROC)曲线分析血清MIP-1α、PD-1对T2DM合并HT的预测价值。结果:糖尿病组和研究组血清MIP-1α、PD-1水平较对照组升高,且研究组血清MIP-1α、PD-1水平较糖尿病组升高(均P<0.05)。两组糖化血红蛋白(HbA1c)、促甲状腺激素(TSH)、游离三碘甲状腺原氨酸(FT3)、游离甲状腺素(FT4)、甲状腺球蛋白抗体(ATG-Ab)、甲状腺过氧化物酶抗体(TPO-Ab)水平比较差异有统计学意义(均P<0.05)。MIP-1α和PD-1与TSH、ATG-Ab、TPO-Ab水平均呈正相关,与FT3、FT4水平呈负相关(均P<0.05)。TSH、TPO-Ab、MIP-1α和PD-1为T2DM合并HT的危险因素(均P<0.05)。MIP-1α、PD-1联合预测T2DM合并HT的曲线下面积(AUC)高于MIP-1α、PD-1单独预测(均P<0.05)。结论:T2DM合并HT患者血清MIP-1α、PD-1水平升高,两项联合对T2DM合并HT具有良好的预测价值。
Abstract:
Objective:To detect the levels of serum macrophage inflammatory protein-1α(MIP-1α)and programmed death-1(PD-1)in patients with type 2 diabetes mellitus(T2DM)complicated with Hashimoto's thyroiditis(HT),and to analyze their predictive value for T2DM complicated with HT.Methods:A total of 46 patients with T2DM complicated with HT were selected as the study group,53 patients with T2DM alone were selected as the diabetes group,and 42 healthy people were selected as the control group.Serum MIP-1α and PD-1 levels and thyroid function related indicators were compared.Pearson method was used to analyze the correlation between serum MIP-1α,PD-1 and thyroid function related indicators.Logistic regression was used to analyze the influencing factors of T2DM complicated with HT.ROC curve was used to analyze the predictive value of serum MIP-1α and PD-1 for T2DM complicated with HT.Results:Compared with the control group,the serum levels of MIP-1α and PD-1 in the diabetes group and the study group were obviously higher,and the serum levels of MIP-1α and PD-1 in the study group were obviously higher than those in the diabetes group(all P<0.05).The levels of HbA1c,TSH,FT3,FT4,ATG-Ab and TPO-Ab in the diabetes group and the study group were statistically different(all P<0.05).MIP-1α and PD-1 were positively correlated with TSH,ATG-Ab and TPO-Ab levels,and negatively correlated with FT3 and FT4 levels(all P<0.05).TSH,TPO-Ab,MIP-1α and PD-1 were risk factors for T2DM complicated with HT(all P<0.05).The AUC of MIP-1α and PD-1 combined in predicting T2DM complicated with HT was higher than that of MIP-1α or PD-1 alone(all P<0.05).Conclusion:The serum levels of MIP-1α and PD-1 are increased in T2DM patients with HT,and the combination of the two has a good predictive value for T2DM complicated with HT.

参考文献/References:

[1] KANALEY J A,COLBERG S R,CORCORAN M H,et al.Exercise/physical activity in individuals with type 2 diabetes:A consensus statement from the american college of sports medicine[J].Med Sci Sports Exerc,2022,54(2):353-368.
[2] ARTASENSI A,PEDRETTI A,VISTOLI G,et al.Type 2 diabetes mellitus:A review of multi-target drugs[J].Molecules,2020,25(8):1987-2006.
[3] 郭利平.葛根芩连汤治疗湿热型2型糖尿病述评[J].陕西中医,2022,43(2):139-144.
[4] HAN M,WU H,YANG W,et al.Analysis of risk factors for the development of type 2 diabetes mellitus complicated with Hashimoto's thyroiditis[J].BMC Endocr Disord,2022,22(1):173-179.
[5] GU L,YANG J,GONG Y,et al.Lower free thyroid hormone levels are associated with high blood glucose and insulin resistance; these normalize with metabolic improvement of type 2 diabetes[J].J Diabetes,2021,13(4):318-329.
[6] RODRIGO M B,DE MIN A,JORCH S K,et al.Dual fluorescence reporter mice for CCL3 transcription,translation,and intercellular communication[J].J Exp Med,2024,221(7):e20231814.
[7] XIAO H,LIANG J,LIU S,et al.Proteomics and organoid culture reveal the underlying pathogenesis of Hashimoto's thyroiditis[J].Front Immunol,2021,12(1):784975-784986.
[8] LEI Z,TANG R,WU Y,et al.TGF-β1 induces PD-1 expression in macrophages through SMAD3/STAT3 cooperative signaling in chronic inflammation[J].JCI Insight,2024,9(7):e165544.
[9] BANCHEREAU R,CHITRE A S,SCHERL A,et al.Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade[J].J Immunother Cancer,2021,9(4):e002231.
[10] 罗百文,李茂城,杨丽梅.Th1/Th2、CD28、ICOS、PD-1和CTLA-4在桥本甲状腺炎患者外周血中的表达及与甲状腺相关实验室指标的相关性[J].检验医学与临床,2023,20(5):589-593.
[11] 中国研究型医院学会糖尿病学专业委员会分级诊疗与基层管理糖尿病学组.2型糖尿病分级诊疗与质量管理专家共识[J].中国医学前沿杂志:电子版,2020,12(5):38-53.
[12] 中华医学会内分泌学分会《中国甲状腺疾病诊治指南》编写.中国甲状腺疾病诊治指南——甲状腺炎[J].中华内科杂志,2008,47(9):784-788.
[13] ZHU W,DONG X,PAN Q,et al.The association between albuminuria and thyroid antibodies in newly diagnosed type 2 diabetes mellitus patients with Hashimoto's thyroiditis and euthyroidism[J].BMC Endocr Disord,2020,20(1):172-176.
[14] FENG F,ZHOU B,ZHOU C L,et al.Vitamin D,selenium,and antidiabetic drugs in the treatment of type 2 diabetes mellitus with Hashimoto's thyroiditis[J].World J Diabetes,2024,15(2):209-219.
[15] 王李宁,牟淑敏.扶正解毒消瘿方治疗正虚痰毒瘀互结型桥本甲状腺炎临床研究[J].陕西中医,2023,44(2):205-208.
[16] 孙莉萍,孟军,张毅,等.2型糖尿病合并桥本甲状腺炎患者血清微小RNA-22-5p和25羟维生素D水平变化及其预测价值研究[J].陕西医学杂志,2023,52(9):1177-1180,1185.
[17] ANNUNZIATA M,ARCADIO F,BORRIELLO A,et al.A novel plasmonic optical-fiber-based point-of-care test for periodontal MIP-1α detection[J].iScience,2023,26(12):108539-108551.
[18] SHENG D,MA W,ZHANG R,et al.CCL3 enhances docetaxel chemosensitivity in breast cancer by triggering proinflammatory macrophage polarization[J].J Immunother Cancer,2022,10(5):e003793.
[19] 亢相逢,曹玲,崔巍,等.哮喘患儿外周血MMP-9、IFN-γ及MIP-1α水平变化及其与肺功能相关性研究[J].陕西医学杂志,2019,48(11):1464-1467.
[20] ZHANG J,LI K,QIU X.Exploring causal correlations between inflammatory cytokines and knee osteoarthritis:A two-sample Mendelian randomization[J].Front Immunol,2024,15(1):1362012-1362021.
[21] HAN Y,LIU D,LI L.PD-1/PD-L1 pathway:Current researches in cancer[J].Am J Cancer Res,2020,10(3):727-742.
[22] GHOSH C,LUONG G,SUN Y.A snapshot of the PD-1/PD-L1 pathway[J].J Cancer,2021,12(9):2735-2746.
[23] CANAVAN M,FLOUDAS A,VEALE D J,et al.The PD-1:PD-L1 axis in inflammatory arthritis[J].BMC Rheumatol,2021,5(1):1-10.
[24] HU Y,ZHANG L,CHEN H,et al.Analysis of regulatory T cell subsets and their expression of helios and PD-1 in patients with hashimoto thyroiditis[J].Int J Endocrinol,2019,2019:5368473.
[25] FANG J,YU L,ZHUANG L G,et al.The changes in peripheral blood Th17 and Treg ratios in Hashimoto's thyroiditis are accompanied by differential PD-1/PD-L1 expression[J].Front Endocrinol(Lausanne),2022,13(1):959477-959485.

相似文献/References:

[1]李艳艳,贾 伟△.24h动态心电图在2型糖尿病合并冠心病患者心律诊断中的价值分析[J].陕西医学杂志,2019,(1):61.
[2]郭向东,马 波△.2型糖尿病患者血清胰岛素水平与骨代谢关联研究*[J].陕西医学杂志,2019,(1):77.
　GUO Xiangdong,MA Bo..Association between serum insulin level and bone metabolismin patients with type 2 diabetes mellitus[J].,2019,(3):77.
[3]刘毅龙,陈鹏宇,雷 江,等.SGLT2抑制剂在2型糖尿病合并心血管疾病治疗中的应用研究进展[J].陕西医学杂志,2019,(3):407.
[4]姚爱红.利拉鲁肽治疗2型糖尿病效果及对患者血脂、颈动脉内膜中层厚度的影响[J].陕西医学杂志,2019,(4):518.
　YAO Aihong..Effect of liraglutide on type 2 diabetes mellitus in patients with blood lipids and carotid intimamedia thickness[J].,2019,(3):518.
[5]李忆琴,吴礼凤,余晓君,等.中年2型糖尿病患者病程和HbA1c水平与认知功能相关性研究*[J].陕西医学杂志,2019,(6):722.
[6]徐 琳,贾睿博△,宋民喜,等.颗粒蛋白前体与糖尿病肾病关系探讨*[J].陕西医学杂志,2019,(8):1024.
[7]王荣锋,郁 昊,蒋新建.老年糖尿病患者血清25羟维生素D水平与骨质疏松相关性研究[J].陕西医学杂志,2019,(8):1032.
　WANG Rongfeng,YU Hao,JIANG Xinjian..The relationship between serum 25 hydroxy vitamin D and osteoporosis in elderly diabetic patients[J].,2019,(3):1032.
[8]王 荣,贾爱华,刘新艳 ,等.IGF1及其相关性因素对2型糖尿病并发骨质疏松的影响研究[J].陕西医学杂志,2019,(9):1163.
　WANG Rong,JIA Aihua,LIU Xinyan,et al.The effect of IGF1 and its related factors in type 2 diabetes complicated with osteoporosis[J].,2019,(3):1163.
[9]贾睿博,徐 琳△.2型糖尿病患者下肢血管病变相关危险因素调查研究[J].陕西医学杂志,2019,(11):1567.
[10]郭建强,赵俊宏,张分队,等.2型糖尿病视网膜病变患者血清HbA1c、CysC检测及临床意义*[J].陕西医学杂志,2020,49(5):619.
　GUO Jianqiang,ZHAO Junhong,ZHANG Fendui,et al.Changes of serum HbA1c and CysC in patients with type 2 diabetic retinopathy and their clinical significance[J].,2020,49(3):619.
[11]孙莉萍,孟 军,张 毅,等.2型糖尿病合并桥本甲状腺炎患者血清微小RNA-22-5p和25羟维生素D水平变化及其预测价值研究[J].陕西医学杂志,2023,52(9):1177.[doi:DOI:10.3969/j.issn.1000-7377.2023.09.014]
　SUN Liping,MENG Jun,ZHANG Yi,et al.Changes and predictive value of serum microRNA-22-5p and 25-hydroxyvitamin D levels in patients with type 2 diabetes mellitus complicated with Hashimoto's thyroiditis[J].,2023,52(3):1177.[doi:DOI:10.3969/j.issn.1000-7377.2023.09.014]

备注/Memo

备注/Memo:
[基金项目]四川省卫生健康科研课题(19PJ056)
更新日期/Last Update: 2025-03-05